Alkem’s Q1 FY27: Revenue grows 11%, but PAT falls on tax impact

Alkem Laboratories opened FY27 with steady operating momentum. Revenue from operations rose to INR 3,740.2 crores in Q1 FY27, up 10.9% year on year. EBITDA stood at INR 766.1 crores, translating into a 20.5% margin. The quarter’s weak point was reported profit after tax, which fell 21.7% year on year to INR 520.0 crores. On the earnings call, management attributed the PAT decline primarily to taxation, with profit before tax before exceptional items broadly flat, up 1.8%.

The quarter also carried two clear messages. First, the core India and international businesses delivered growth, with non-US markets showing sharp acceleration. Second, execution and risk management will matter more than ever, with a USFDA OAI for the Daman formulations facility and higher investments underway in R and D, CDMO, MedTech, and biotech-linked initiatives.

A quarter of mixed signals: strong gross margin, softer EBITDA margin

The P and L shows a better gross profit profile but a lower EBITDA margin versus last year. Gross profit rose 15.4% year on year to INR 2,538.9 crores, and gross margin expanded to 67.9% from 65.3% in Q1 FY26. In the concall, the CFO linked this improvement to a better mix, supported by lower trade generics growth and relatively stronger prescription business, along with currency benefits on international sales.

At the EBITDA level, the margin declined to 20.5% from 21.9% last year, even as EBITDA grew 3.7% year on year. Management explained that employee costs increased due to annual increments, the addition of around 1,200 medical representatives over the last few quarters, and staffing for the Enzene CDMO business which became operational from November 2025. Other expenses were also impacted by Enzene CDMO costs and the translation impact of a higher USD-INR conversion rate on foreign subsidiary expenses.

R and D spending continued to move higher. Q1 FY27 R and D expenses were INR 150.2 crores, equivalent to 4.0% of revenue, versus INR 118.4 crores and 3.5% in Q1 FY26.

India business: outperformance versus IPM, but trade generics slows growth

India remains the largest contributor, with domestic sales of INR 2,497.8 crores in Q1 FY27, up 10.3% year on year, and accounting for 67.1% of total sales. The investor deck cited IQVIA SSA data showing Alkem growth of 13.2% year on year versus 12.2% for the Indian Pharmaceutical Market, a 100 bps outperformance. The company also highlighted outperformance across multiple therapies including anti-infectives, gastro-intestinal, vitamins minerals nutrients, pain, anti-diabetic, respiratory and dermatology.

Still, the earnings call clarified why headline domestic growth looked slower relative to peers. Management said trade generics was flat to mildly up in the quarter and dragged the overall India growth, given its meaningful contribution to domestic formulations. The MD also stated branded business growth was 12%.

The CFO provided additional drivers for the prescription business excluding trade generics: price growth of around 6%, new launches around 3%, and volume around 2% for the quarter. On sustainability of market growth, management did not indicate a structural change in demand, but noted chronic therapies may be supported by factors such as semaglutide going off patent, while also indicating their own semaglutide contribution remains small.

International business: non-US accelerates, US stays cautious with regulatory overhang

International sales grew 16.0% year on year to INR 1,222.3 crores. Within this, US sales rose 6.5% year on year to INR 743.9 crores, while non-US sales jumped 34.5% to INR 478.5 crores. The non-US contribution rose to 12.9% of total sales from 10.8% last year.

On the call, management described non-US growth as sustainable but acknowledged that several markets are still small in absolute terms. Chile and Australia were specifically mentioned as larger markets for Alkem that performed well.

The US outlook remains more measured. Management cited price erosion as a key headwind and agreed with the view that recent launches have not driven meaningful volume expansion yet. For the full year, management guided to high single digit to mid single digit US growth, with currency expected to help.

A key risk disclosed in the presentation is the regulatory status of the Daman formulations facility. The facility received an Official Action Indicated classification in August 2026 following an April 2026 inspection. In the earnings call, management stated around 45% of US revenue comes from this facility and confirmed that supply continues. Management said the OAI is a concern, but does not expect it to impact FY27 business and expects to come out of it in 6 to 12 months.

New growth vectors: CDMO economics and MedTech integration take centre stage

Two newer verticals were discussed in greater detail on the call: US CDMO operations through Enzene and the MedTech acquisition of Occlutech.

For US CDMO, management disclosed operating expenses of around INR 60 crores per quarter. They said these costs are hard to cut given the complexity of US operations, and the focus must be on building revenues. Breakeven, as per management, requires about USD 25 million to USD 30 million of annualized revenue. The company is targeting monoclonal antibodies CDMO work, primarily development and clinical trial supplies today, with management emphasizing long sales cycles and dependency on client funding and clinical progress. Revenue ramp was indicated in FY27 and FY28.

On MedTech, management clarified that Occlutech was acquired in mid-July 2026, so Q1 consolidated numbers were not impacted. Due to delays in completing integration versus the original plan, the company now targets around INR 400 crores of sales for roughly 8.5 months of FY27 with breakeven EBITDA. Management expects margin improvement through integration with India operations from the next quarter and expects to reach medium-term margin guidance over 3 to 4 years.

In parallel, the company also discussed the existing ortho medical device business acquired earlier, stating that excluding diligence and Occlutech costs, this business had an EBITDA loss of around INR 5 crores to INR 7 crores as the company invests and files products outside India. Management suggested the ortho device business excluding Occlutech could do around INR 50 crores of annual sales and expects it to break even in the next 12 months.

The takeaway: steady core, but execution risks are rising

Alkem’s Q1 FY27 performance shows a company that is still growing consistently across India and international businesses, supported by a strong domestic franchise and fast growth in non-US markets. Gross margins improved, and the balance sheet remains strong with net cash of INR 5,764 crores as of June 30, 2026.

At the same time, the quarter highlighted three execution variables investors will likely track through FY27: the pace of normalization in trade generics, the remediation path and outcomes for the Daman OAI, and the timeline for newer verticals like US CDMO and MedTech to move from investment mode to profitable scale.

Management’s own framing was balanced. They described a steady start to the year, acknowledged areas needing improvement in execution and regulatory priorities, and reiterated that the company is investing in R and D, MedTech and biotech-linked opportunities while trying to strengthen the core. The next few quarters should clarify whether these investments begin to translate into more consistent profit delivery.